Investigating how immune responses affect colorectal cancer outcomes in African Americans
Defining the role of tumoral MHC Class I Expression in Mediating Colorectal Cancer Racial Disparities
['FUNDING_R01'] · OHIO STATE UNIVERSITY · NIH-10894892
This study is looking into why African American patients are more likely to die from colorectal cancer than White patients, focusing on how the immune system responds in these cases, with the hope of finding better treatments that work for everyone.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OHIO STATE UNIVERSITY (nih funded) |
| Locations | 1 site (Columbus, UNITED STATES) |
| Trial ID | NIH-10894892 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding why African American patients experience higher mortality rates from colorectal cancer compared to White patients. It examines the role of immune responses, particularly the expression of MHC class I molecules in tumors, which are crucial for T cell activation. By analyzing tumor samples and immune cell interactions, the study aims to identify mechanisms that contribute to these disparities and develop better biomarkers and therapies. Patients may benefit from insights that could lead to more effective treatments tailored to their specific immune profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American individuals diagnosed with colorectal cancer.
Not a fit: Patients who are not African American or do not have colorectal cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that reduce colorectal cancer disparities among African American patients.
How similar studies have performed: Other research has indicated that understanding immune mechanisms can significantly impact cancer treatment outcomes, suggesting potential for success in this approach.
Where this research is happening
Columbus, UNITED STATES
- OHIO STATE UNIVERSITY — Columbus, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RUBINSTEIN, MARK P — OHIO STATE UNIVERSITY
- Study coordinator: RUBINSTEIN, MARK P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.